Skip to Main content Skip to Navigation

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity

Abstract : Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%-80% of cases. However, the prognosis is still poor for older patients, who are unfit for intensive chemotherapy, and only a few therapies are available. Hypomethylating agents, such as decitabine, are approved for such patients. The current dosing regimen consists of one administration per day, for 5 days, each 4 weeks. Methods: Here, we present the synthesis of a decitabine prodrug, combined with its encapsula-tion into a lipid-based nanocapsule formulation. Decitabine (C12) 2 was synthetized, then loaded into nanocapsules. Its stability in phosphate buffer ans human plasma was checked. Its activity was evaluated by Cell proliferation assays and cell-cycle analysis on human erythroleukemia cells. Then its pharmacokinetics was determined on a rat model. Results: Decitabine (C12) 2 was obtained with a yield of 50%. Drug loading into nanocarriers of 27.45±0.05 nm was 5.8±0.5 mg/mL. The stability of decitabine was improved and its activity on leukemia cells was not altered. Finally, pharmacokinetics studies showed a prolonged mean residence time of the drug. Conclusion: Decitabine (C12) 2 as a prodrug showed high encapsulation efficiency, a good stability in plasma with no impact on its activity on leukemia cells and improved pharmacokinetics.
Document type :
Journal articles
Complete list of metadatas

Cited literature [51 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02516731
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, March 24, 2020 - 8:56:36 AM
Last modification on : Tuesday, March 31, 2020 - 2:00:57 AM

File

briot2019Eq7.pdf
Publication funded by an institution

Identifiers

Citation

Thomas Briot, Emilie Roger, Naila Bou Haidar, Jérôme Bejaud, Nolwenn Lautram, et al.. Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity. International Journal of Nanomedicine, Dove Medical Press, 2019, 14, pp.2091-2102. ⟨10.2147/IJN.s190482⟩. ⟨inserm-02516731⟩

Share

Metrics

Record views

49

Files downloads

94